A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)
2期
提前终止
NCT06113328
| 适应症 | Non-segmental Vitiligo |
|---|
| 分期 | 2期 |
|---|
| 申办方 | Merck Sharp & Dohme LLC |
|---|
| 状态 | 提前终止 |
|---|
| 受试者人数 | 169 人 |
|---|
| 干预（药物） | MK-6194 |
|---|
| 开始日期 | 2023年11月27日 |
|---|
| 完成日期 | 2025年3月20日 |
|---|
| 结果公布日 | 2026年3月17日 |
|---|
摘要
Researchers are looking for a new way to treat people with non-segmental vitiligo (NSV). The goal of this study is to learn about the safety of MK-6194 and how well people tolerate it. Researchers also want to learn if people who take MK-6194 have more of a decrease in the amount of vitiligo on their face compared to people who take placebo.
Percent Change From Baseline in Facial Vitiligo Area Scoring Index (F-VASI) at Week 24
Baseline and Week 24 · Percent change
| MK-6194 3 mg Q2W | -4.55 Percent change |
|---|
| MK-6194 3 mg Q4W | -12.13 Percent change |
|---|
| Placebo | -4.01 Percent change |
|---|
| p-value | 0.949 |
|---|
| Mean Difference (Final Values) | -0.55 (95% CI -17.47–16.38) |
|---|
Number of Participants Who Experienced an Adverse Event (AE)
Up to approximately 28 weeks · Participants
| MK-6194 3 mg Q2W | 51 Participants |
|---|
| MK-6194 3 mg Q4W | 47 Participants |
|---|
| Placebo | 44 Participants |
|---|
Number of Participants Who Discontinued Study Treatment Due to an AE
Up to approximately 24 weeks · Participants
| MK-6194 3 mg Q2W | 9 Participants |
|---|
| MK-6194 3 mg Q4W | 5 Participants |
|---|
| Placebo | 1 Participants |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。